SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Inspira Technologies OXY B.H.N. Ltd. – ‘20-F/A’ for 12/31/22

On:  Wednesday, 4/19/23, at 5:42pm ET   ·   As of:  4/20/23   ·   For:  12/31/22   ·   Accession #:  1213900-23-31088   ·   File #:  1-40303

Previous ‘20-F’:  ‘20-F’ on 3/31/23 for 12/31/22   ·   Next & Latest:  ‘20-F’ on 3/25/24 for 12/31/23   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/20/23  Inspira Techs OXY B.H.N. Ltd.     20-F/A     12/31/22  101:5.8M                                   EdgarAgents LLC/FA

Amendment to Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F/A      Amendment No. 1 to Form 20-F                        HTML    859K 
 4: EX-13.1     Annual or Quarterly Report to Security Holders      HTML     26K 
 5: EX-13.2     Annual or Quarterly Report to Security Holders      HTML     26K 
 2: EX-12.1     Statement re: the Computation of Ratios             HTML     31K 
 3: EX-12.2     Statement re: the Computation of Ratios             HTML     31K 
11: EX-15.1     Consent of Ziv Haft, A Member Firm of Bdo,          HTML     27K 
                Independent Registered Public Accounting Firm                    
12: R1          Document And Entity Information                     HTML    100K 
13: R2          Statements of Financial Position                    HTML     85K 
14: R3          Statements of Comprehensive Loss                    HTML     63K 
15: R4          Statements of Comprehensive Loss (Parentheticals)   HTML     29K 
16: R5          Statements of Changes in Shareholders? Equity       HTML     82K 
17: R6          Statements of Cash Flow                             HTML    106K 
18: R7          General                                             HTML     37K 
19: R8          Significant Accounting Policies                     HTML     74K 
20: R9          Critical Accounting Estimates and Judgements        HTML     32K 
21: R10         Deposits                                            HTML     30K 
22: R11         Other Current Assets                                HTML     32K 
23: R12         Property and Equipment, Net                         HTML     55K 
24: R13         Other Accounts Payable                              HTML     32K 
25: R14         Liability in Respect of Government Grants           HTML     34K 
26: R15         Finacial Liabilities at Fair Value                  HTML     39K 
27: R16         Equity (Defict)                                     HTML     44K 
28: R17         Research and Development Expenses                   HTML     34K 
29: R18         Sales and Marketing Expenses                        HTML     33K 
30: R19         General and Administrative Expenses                 HTML     36K 
31: R20         Financial (Income) and Expenses                     HTML     38K 
32: R21         Taxes on Income                                     HTML     35K 
33: R22         Leases                                              HTML     46K 
34: R23         Share Based Compensation                            HTML     66K 
35: R24         Related Parties                                     HTML     34K 
36: R25         Financial Instruments and Risk Management           HTML     53K 
37: R26         Commitments and Contingencies                       HTML     36K 
38: R27         Fair Value Measurement                              HTML     50K 
39: R28         Accounting Policies, by Policy (Policies)           HTML    107K 
40: R29         Significant Accounting Policies (Tables)            HTML     30K 
41: R30         Other Current Assets (Tables)                       HTML     32K 
42: R31         Property and Equipment, Net (Tables)                HTML     53K 
43: R32         Other Accounts Payable (Tables)                     HTML     31K 
44: R33         Liability in Respect of Government Grants (Tables)  HTML     32K 
45: R34         Finacial Liabilities at Fair Value (Tables)         HTML     32K 
46: R35         Equity (Defict) (Tables)                            HTML     38K 
47: R36         Research and Development Expenses (Tables)          HTML     34K 
48: R37         Sales and Marketing Expenses (Tables)               HTML     33K 
49: R38         General and Administrative Expenses (Tables)        HTML     35K 
50: R39         Financial (Income) and Expenses (Tables)            HTML     39K 
51: R40         Taxes on Income (Tables)                            HTML     33K 
52: R41         Leases (Tables)                                     HTML     44K 
53: R42         Share Based Compensation (Tables)                   HTML     54K 
54: R43         Related Parties (Tables)                            HTML     34K 
55: R44         Financial Instruments and Risk Management (Tables)  HTML     52K 
56: R45         Fair Value Measurement (Tables)                     HTML     47K 
57: R46         General (Details)                                   HTML     50K 
58: R47         Significant Accounting Policies (Details) -         HTML     40K 
                Schedule of straight-line basis, over the useful                 
                lives of the assets                                              
59: R48         Deposits (Details)                                  HTML     32K 
60: R49         Other Current Assets (Details) - Schedule of other  HTML     36K 
                Current Assets                                                   
61: R50         Property and Equipment, Net (Details) - Schedule    HTML     68K 
                of property and equipment, net                                   
62: R51         Other Accounts Payable (Details) - Schedule of      HTML     36K 
                other accounts payable                                           
63: R52         Liability in Respect of Government Grants           HTML     31K 
                (Details)                                                        
64: R53         Liability in Respect of Government Grants           HTML     37K 
                (Details) - Schedule of reimbursement of research                
                expenses                                                         
65: R54         Finacial Liabilities at Fair Value (Details)        HTML     63K 
66: R55         Finacial Liabilities at Fair Value (Details) -      HTML     38K 
                Schedule of finacial liabilities at fair value                   
67: R56         Equity (Defict) (Details)                           HTML     86K 
68: R57         Equity (Defict) (Details) - Schedule of share       HTML     32K 
                capital                                                          
69: R58         Equity (Defict) (Details) - Schedule of loss per    HTML     36K 
                share                                                            
70: R59         Equity (Defict) (Details) - Schedule of loss per    HTML     29K 
                share (Parentheticals)                                           
71: R60         Research and Development Expenses (Details) -       HTML     39K 
                Schedule of research and development expenses                    
72: R61         Sales and Marketing Expenses (Details) - Schedule   HTML     38K 
                of sales and Marketing Expenses                                  
73: R62         General and Administrative Expenses (Details) -     HTML     49K 
                Schedule of general and administrative expenses                  
74: R63         Financial (Income) and Expenses (Details) -         HTML     39K 
                Schedule of financial income                                     
75: R64         Financial (Income) and Expenses (Details) -         HTML     40K 
                Schedule of financial expenses                                   
76: R65         Taxes on Income (Details)                           HTML     32K 
77: R66         Taxes on Income (Details) - Schedule of             HTML     38K 
                theoretical tax                                                  
78: R67         Taxes on Income (Details) - Schedule of             HTML     28K 
                theoretical tax (Parentheticals)                                 
79: R68         Leases (Details)                                    HTML     41K 
80: R69         Leases (Details) - Schedule of right-of-use assets  HTML     45K 
81: R70         Leases (Details) - Schedule of lease liabilities    HTML     43K 
82: R71         Leases (Details) - Schedule of profit or loss       HTML     33K 
83: R72         Share Based Compensation (Details)                  HTML    103K 
84: R73         Share Based Compensation (Details) - Schedule of    HTML     60K 
                options to services providers and advisers                       
                outstanding                                                      
85: R74         Share Based Compensation (Details) - Schedule of    HTML     42K 
                RSUs to services providers and advisers                          
                outstanding                                                      
86: R75         Related Parties (Details) - Schedule of             HTML     31K 
                shareholders and other related parties? benefits                 
87: R76         Related Parties (Details) - Schedule of balances    HTML     34K 
                with related parties                                             
88: R77         Financial Instruments and Risk Management           HTML     30K 
                (Details)                                                        
89: R78         Financial Instruments and Risk Management           HTML     39K 
                (Details) - Schedule of financial assets                         
                represents the maximum credit exposure                           
90: R79         Financial Instruments and Risk Management           HTML     42K 
                (Details) - Schedule of foreign currency                         
                denominated monetary liability                                   
91: R80         Financial Instruments and Risk Management           HTML     34K 
                (Details) - Schedule of sensitivity analysis                     
92: R81         Financial Instruments and Risk Management           HTML     46K 
                (Details) - Schedule of cash flows of financial                  
                liabilities                                                      
93: R82         Commitments and Contingencies (Details)             HTML     32K 
94: R83         Fair Value Measurement (Details)                    HTML     46K 
95: R84         Fair Value Measurement (Details) - Schedule of      HTML     46K 
                warrants                                                         
96: R85         Fair Value Measurement (Details) - Schedule of      HTML     53K 
                movements in level 2 liability                                   
99: XML         IDEA XML File -- Filing Summary                      XML    192K 
97: XML         XBRL Instance -- f20f2022a1_inspirat_htm             XML   1.29M 
98: EXCEL       IDEA Workbook of Financial Reports                  XLSX    163K 
 7: EX-101.CAL  XBRL Calculations -- iinn-20221231_cal               XML    110K 
 8: EX-101.DEF  XBRL Definitions -- iinn-20221231_def                XML    843K 
 9: EX-101.LAB  XBRL Labels -- iinn-20221231_lab                     XML   1.67M 
10: EX-101.PRE  XBRL Presentations -- iinn-20221231_pre              XML    837K 
 6: EX-101.SCH  XBRL Schema -- iinn-20221231                         XSD    365K 
100: JSON        XBRL Instance as JSON Data -- MetaLinks              358±   509K  
101: ZIP         XBRL Zipped Folder -- 0001213900-23-031088-xbrl      Zip    248K  


‘20-F/A’   —   Amendment No. 1 to Form 20-F

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Explanatory Note
"Part Iii
"Financial Statements
"Exhibits
"Signatures
"Report of Independent Registered Public Accounting Firm (BDO Ziv Haft ; Tel-Aviv, Israel ; PCAOB# 1185 )
"Statements of financial position
"Statements of comprehensive loss
"Statements of changes in shareholders' equity
"Statements of cash flows
"Notes to the financial statements

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM  i 20-F/A

(Amendment No. 1)

 

 i  REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 i  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended  i  i December 31,  i 2022 / 

 

OR

 

 i  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

OR

 

 i  SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File No.:  i 001-40303

 

 i INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

(Exact name of registrant as specified in its charter)

 

Translation of registrant’s name into English: Not applicable

 

State of  i Israel

(Jurisdiction of incorporation or organization)

 

 i 2 Ha-Tidhar St.,

 i Ra’anana,  i 4366504  i Israel

Tel: + i 972.4. i 6230333

(Address of principal executive offices)

 

 i Dagi Ben-Noon

 i 2 Ha-Tidhar St.,

 i Ra’anana,  i 4366504  i Israel

Tel: +972.4.6230333

 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
 i Ordinary Shares, no par value    i IINN    i Nasdaq Capital Market
Warrant to purchase one Ordinary Share   IINNW    

 

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

 

 

 

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:

 

 i 11,338,940 ordinary shares as of December 31, 2022.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 

Yes ☐     i No

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.

 

Yes ☐     i No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

 

Yes ☐     i No ☒ 

 

Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.

 

 i Yes ☒    No ☐ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
   i Non-accelerated filer Emerging Growth Company  i 

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.  i 

 

†The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

Yes ☐    No  i 

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

 

U.S. GAAP ☐

 

International Financial Reporting Standards as issued by the International Accounting Standards Board

 

Other ☐

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

 

☐ Item 17   ☐ Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company.

 

Yes ☐    No  i 

 

 

 

 

 

EXPLANATORY NOTE

 

 i 

We are filing this Amendment No. 1 (this “Amendment”) to our Annual Report on Form 20-F (the “Original Filing”) for the sole purpose of amending Item 18 of the Original Filing to amend the date of the auditor’s opinion located on page F-2 of this Amendment. For clarity, the audited consolidated financial statements as of and for the fiscal years ended December 31, 2022, 2021, and 2020 included in this Amendment No. 1 are unchanged from the audited consolidated financial statements included in the Original Filing.

 

In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment No. 1 as Exhibits 12.1, 12.2, 13.1 and 13.2.

 

Other than expressly set forth herein, this Amendment No. 1 does not, and does not purport to, amend or restate any other information contained in the Original Filing nor does this Amendment No. 1 reflect any events that have occurred after the Original Filing was filed.

 

i

 

 

TABLE OF CONTENTS

 

    Page
EXPLANATORY NOTE
PART III
ITEM 17. FINANCIAL STATEMENTS 1
ITEM 18. FINANCIAL STATEMENTS 1
ITEM 19. EXHIBITS. 1
SIGNATURES 2

 

ii

 

 

PART III

 

ITEM 17. FINANCIAL STATEMENTS

 

We have elected to provide financial statements and related information pursuant to Item 18.

 

ITEM 18. FINANCIAL STATEMENTS

 

The consolidated financial statements and the related notes required by this Item are included in this Amendment No. 1 to our annual report on Form 20-F beginning on page F-1.

 

ITEM 19. EXHIBITS.

 

Number   Exhibit Description
1.1   Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303) filed on December 20, 2021 and incorporated herein by reference).
2.1  
4.1   Form of Indemnification Agreement. (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated herein by reference).
4.2   Inspira Technologies Oxy B.H.N. Ltd. (formerly known as: InSense Medical Ltd.) 2019 Equity Incentive Plan (amended on September 14, 2021), filed as Exhibit 10.2 to Post-Effective Amendment No. 1 to Form F-1 (File No. 333-253920) filed on October 27, 2021, and incorporated herein by reference.
4.3   Inspira Technologies Oxy B.H.N. Ltd. Compensation Policy for Company’s Executives, filed as Exhibit 99.2 to Form 6-K (File No. 001-4030) filed on December 20, 2021, and incorporated herein by reference.
4.4   Form of Warrant (filed as Exhibit 4.4 to form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference).
4.5   Form of Simple Agreement for Future Equity (filed as Exhibit 10.7 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)
4.6   Shareholder Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference).
4.7   Form of Convertible Loan Agreement (filed as Exhibit 10.9 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)
12.1*   Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.
12.2*   Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.
13.1%   Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350.
13.2%   Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350.
15.1*   Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.
101*   The following financial information from the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance sheets as of December 31, 2022, December 31, 2021 and December 31, 2020; (ii) Consolidated Statements of Comprehensive Loss as of December 31, 2022, December 31, 2021 and December 31, 2020; (iii) Consolidated Statement of Changes in Shareholders’ Equity as of December 31, 2022, December 31, 2021 and December 31, 2020; (iv) Consolidated Statements of Cash Flows as of December 31, 2022, December 31, 2021 and December 31, 2020; and (v) Notes to the consolidated financial statements.
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.
% Furnished herewith

 

1

 

 

SIGNATURES

 

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on Form 20-F filed on its behalf.

 

  INSPIRA TECHNOLOGIES OXY B.H.N. LTD.
     
Date: April 19, 2023 By: /s/ Dagi Ben-Noon
    Dagi Ben-Noon
    Chief Executive Officer

 

2

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

 

TABLE OF CONTENTS

 

    Page
     
Report of Independent Registered Public Accounting Firm (BDO  i Ziv Haft;  i Tel-Aviv, Israel; PCAOB# i 1185)   F-2
Statements of financial position   F-3
Statements of comprehensive loss   F-4
Statements of changes in shareholders’ equity   F-5
Statements of cash flows   F-8
Notes to the financial statements   F-10-F-37

  

______________________

________________

____________

 

The amounts are stated in thousands of U.S. dollars

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To The Board of Directors and Shareholders of Inspira Technologies Oxy B.H.N. Ltd.

Ha-Tidhar Street 2, Rananna, Israel

 

Opinion on the Financial Statements 

 

We have audited the accompanying statements of financial position of Inspira Technologies Oxy B.H.N. Ltd. (formerly: Insense Medical Ltd.) (the “Company”) as of December 31, 2022 and 2021, the related statements of comprehensive loss, changes in shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively, the “Financial Statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. 

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. 

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Tel-Aviv, Israel /s/ Ziv Haft
March 28, 2023 Certified Public Accountants (Isr.)
We have served as the Company’s auditor since 2018. BDO Member Firm /s/

 

F-2

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF FINANCIAL POSITION

(US dollars in thousands)

 

       December 31,   December 31, 
   Note   2022   2021 
ASSETS            
Current Assets            
Cash and cash equivalents         i 6,783     i 23,749 
Deposits   4     i 7,120    
-
 
Other current assets   5     i 591     i 759 
Total current assets         i 14,494     i 24,508 
                
Non-Current Assets:               
Right of use assets, net   16     i 1,107     i 1,160 
Property, plant and equipment, net   6     i 411     i 202 
Total non-current assets         i 1,518     i 1,362 
Total Assets         i 16,012     i 25,870 
                
LIABILITIES AND SHAREHOLDERS’ EQUITY               
Current Liabilities:               
Trade accounts payables         i 150     i 93 
Other accounts payables   7     i 1,217     i 725 
Lease liabilities   16     i 329     i 281 
Financial liabilities at fair value   9     i 368     i 3,215 
Total current liabilities         i 2,064     i 4,314 
                
Non-Current Liabilities:               
Lease liabilities   16     i 728     i 900 
Loan from the Israeli Innovation Authority   8     i 398     i 302 
Total non- current liabilities         i 1,126     i 1,202 
                
Shareholders’ Equity:               
Share capital and additional paid in capital   10     i 53,814     i 48,935 
Foreign exchange reserve        ( i 1,928)    i 210 
Accumulated deficit        ( i 39,064)   ( i 28,791)
Total Shareholders’ Equity         i 12,822     i 20,354 
Total liabilities and Shareholders’ Equity         i 16,012     i 25,870 

 

/s/ Yafit Tehila   /s/ Dagi Ben-Noon   March 28, 2023

Yafit Tehila
Chief Financial Officer

 

Dagi Ben-Noon
Chief Executive Officer

  Date of approval of financial statements

 

The accompanying notes are an integral part of the financial statements.

 

F-3

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF COMPREHENSIVE LOSS

(US dollars in thousands except for loss per share)

 

       Year ended
December 31,
 
   Note   2022   2021   2020 
                 
Research and development expenses   11     i 8,054     i 3,909     i 3,873 
Sales and marketing expenses   12     i 1,325     i 1,951    
-
 
General and administrative expenses   13     i 5,391     i 7,572     i 2,447 
Other income        
-
    
-
     i 51 
Operating loss         i 14,770     i 13,432     i 6,269 
Finance expense   14     i 181     i 3,524     i 959 
Finance income   14    ( i 4,678)   ( i 1)   
-
 
Loss before tax         i 10,273     i 16,955     i 7,228 
Taxes on income        
-
    
-
    
-
 
Total net loss         i 10,273     i 16,955     i 7,228 
                     
Other comprehensive loss, net of tax:                    
Items that will not be reclassified to profit or loss:                    
Exchange (losses)profits arising on translation to presentation currency        ( i 2,138)    i 845    ( i 599)
Total comprehensive loss         i 12,411     i 16,110     i 7,827 
Weighted average number of ordinary shares         i 10,794,594     i 5,306,225     i 1,967,790 
Basic and diluted loss per share
        ( i 0.95)   ( i 3.2)   ( i 3.67)

 

The accompanying notes are an integral part of the financial statements.

 

F-4

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(US dollars in thousands)

 

For the year ended December 31, 2022:

 

   Ordinary Share Capital             
   Number of shares   Share capital and
Additional Paid in Capital
   Adjustments arising from translating financial operation   Accumulated deficit   Total 
                     
Balance as of January 1, 2022:    i 10,091,706     i 48,935     i 210    ( i 28,791)    i 20,354 
                          
Changes during the period:                         
Net loss   -    
-
    
-
    ( i 10,273)   ( i 10,273)
Other comprehensive loss   -    
-
    ( i 2,138)   
-
    ( i 2,138)
Total comprehensive loss             ( i 2,138)   ( i 10,273)   ( i 12,411)
Share based compensation to exercise    i 7,030    *    
-
    
-
    
-
 
RSUs vesting    i 1,240,204    
-
    
-
    
-
    
-
 
Share based compensation   -     i 4,879    -    -     i 4,879 
Balance as of December 31, 2022    i 11,338,940     i 53,814    ( i 1,928)   ( i 39,064)    i 12,822 

 

(*)Less than thousand dollars

 

The accompanying notes are an integral part of the financial statements.

 

F-5

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(US dollars in thousands)

 

For the year ended December 31, 2021:

 

   Ordinary Share Capital     Additional     Adjustments arising from translating         
   Number of shares   Share capital   Paid in Capital   financial operation   Accumulated deficit   Total 
                         
Balance as of January 1, 2021:    i 2,661,095     i 304     i 10,463    ( i 635)   ( i 11,836)   ( i 1,704)
                               
Changes during the period:                              
Net loss   -    
-
    
-
    
-
    ( i 16,955)   ( i 16,955)
Other comprehensive loss   -    
-
    
-
     i 845    
-
     i 845 
Total comprehensive loss        
-
    
-
     i 845    ( i 16,955)   ( i 16,110)
Par value cancellation   -    ( i 304)    i 304    
-
    
-
    
-
 
Initial Public Offering (“IPO”)    i 2,931,472    
-
     i 9,852    
-
    
-
     i 9,852 
Conversion of financial liability    i 2,113,905    
-
     i 10,041    
-
    
-
     i 10,041 
Tradable warrants exercise    i 1,705,000    
-
     i 11,447    
-
    
-
     i 11,447 
RSUs vesting    i 655,603    
-
    
-
    
-
    
-
    
-
 
Share based compensation to exercise    i 24,631    *    
-
    
-
    
-
    
-
 
Share based compensation   -    
-
     i 6,828    
-
    
-
     i 6,828 
Balance as of December 31, 2021    i 10,091,706    -     i 48,935     i 210    ( i 28,791)    i 20,354 

 

(*)Less than thousand dollars

 

The accompanying notes are an integral part of the financial statements.

 

F-6

 

  

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(US dollars in thousands)

 

For the year ended December 31, 2020:

 

   Ordinary Share Capital   Additional   Adjustments arising from translating         
   Number of shares   Share capital   Paid in Capital   financial operation   Accumulated deficit   Total 
                         
Balance as of January 1, 2020:    i 1,904,762     i 3    
-
    ( i 36)   ( i 4,608)   ( i 4,641)
                               
Changes during the period:                              
Net loss   -    
-
    
-
    
-
    ( i 7,228)   ( i 7,228)
Other comprehensive loss   -    
--
         ( i 599)   
-
    ( i 599)
Total comprehensive loss   -    
-
    
-
    ( i 599)   ( i 7,228)   ( i 7,827)
Share split   -     i 215    ( i 215)   
-
    
-
      
Share based compensation   -    
-
     i 3,896    
-
    
-
     i 3,896 
Share based compensation to exercise   -     i 9    ( i 9)   
-
    
-
    
-
 
Conversion of convertible loan to shares    i 756,333     i 77     i 6,791    
-
    
-
     i 6,868 
Balance as of December 31, 2020    i 2,661,095     i 304     i 10,463    ( i 635)   ( i 11,836)   ( i 1,704)

 

The accompanying notes are an integral part of the financial statements.

 

F-7

 

 

 INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF CASH FLOW

(US dollars in thousands)

 

   Year ended December 31 
   2022   2021   2020 
             
CASH FLOW FROM OPERATING ACTIVITIES:            
Net loss   ( i 10,273)   ( i 16,955)   ( i 7,228)
Adjustments to reconcile net loss to net cash provided by operating activities:               
Depreciation    i 361     i 237     i 203 
Exercise of warrants   
-
    
-
     i 204 
Share based compensation    i 4,879     i 6,630     i 3,896 
Revaluation of financial liabilities accounted at fair value   ( i 2,592)    i 2,313     i 689 
Changes of financial liabilities - IPO non-cash expenses   
-
     i 219    
-
 
Change in connection to loan from the Israeli Innovation Authority   
-
    ( i 180)   
-
 
Financial expenses   ( i 459)    i 92     i 12 
Changes in operating assets and liability               
Decrease (increase) in other current assets    i 29    ( i 468)    i 10 
Increase (decrease) in trade accounts payables    i 71     i 87    ( i 70)
Increase in other accounts payable    i 604     i 148     i 408 
Net cash used in operating activities   ( i 7,380)   ( i 7,877)   ( i 1,876)
                
CASH FLOW FROM INVESTING ACTIVITIES:               
Purchase of property, plant, and equipment   ( i 304)   ( i 176)   ( i 23)
Payment of deposit    i 55    ( i 70)   ( i 3)
Change of deposit   ( i 7,000)   
-
    
-
 
Net cash used in investing activities   ( i 7,249)   ( i 246)   ( i 26)
                
CASH FLOWS FROM FINANCING ACTIVITIES:               
Principal paid on lease liabilities   ( i 399)   ( i 199)   ( i 176)
Receipt of simple agreements for future equity (SAFE) and convertible loan   
-
     i 7,208     i 2,157 
Receipt of IPO funds   
-
     i 14,658    
-
 
Receipt of warrants exercise funds, net from fees   
-
     i 8,721    
-
 
Loan from the Israeli Innovation Authority   
-
     i 34     i 308 
Net cash provided by (used in) financing activities   ( i 399)    i 30,422     i 2,289 
                
Net increase (decrease) in cash and cash equivalents   ( i 15,028)    i 22,299     i 387 
Cash and cash equivalents at the beginning of the period    i 23,749     i 496     i 96 
Effects of exchange rate changes on cash and cash equivalents   ( i 1,938)    i 954     i 13 
Cash and cash equivalents at the end of the period    i 6,783     i 23,749     i 496 

 

The accompanying notes are an integral part of the financial statements

 

F-8

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

STATEMENTS OF CASH FLOW

(US dollars in thousands)

 

APPENDIX A – NON-CASH TRANSACTIONS:

 

   Year ended December 31, 
   2022   2021   2020 
             
Conversion of convertible loans to equity   
-
     i 10,041    
-
 
Tradable warrants at the IPO date   
-
    ( i 4,373)   
-
 
Tradable warrants financial liability at the IPO date   
-
    ( i 234)   
-
 
Share based compensation – underwriters fees at the IPO date   
-
     i 198    
-
 
Warrants exercise to equity – financial liability   
-
     i 656    
-
 
Warrants exercise – allocation from liability to equity   
-
     i 2,070    
-
 
    
-
     i 8,358    
-
 

 

APPENDIX B - AMOUNT PAID DURING THE PERIOD:

 

   Year ended December 31, 
   2022   2021   2020 
Interest paid    i 37     i 6     i 45 

 

The accompanying notes are an integral part of the financial statements

 

F-9

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 1 - GENERAL:

 

1. Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical Ltd.) (the “Company”) was incorporated in Israel and commenced its operations on February 27, 2018. The Company’s functional currency is the New Israeli Shekel (“NIS”).

 

The Company operates in the medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing related activities, and go to market activities of proprietary products and technologies. The Company is developing the following products:

 

(*)The INSPIRA ART (Augmented Respiratory Technology), which is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient saturation levels within minutes while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical ventilation, with the potential to reduce risks, complications and high costs.

 

(*) The HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time and continuous blood measurements, potentially minimizing the need to take actual blood samples from patients.

 

(*)The ALICE Device, an advanced form of life support system better known by the medical industry as a cardiopulmonary bypass system is being designed for use in surgical procedures requiring cardiopulmonary bypass for six hours or less.

 

2. The Company’s products are in the development stage. The ALICE device and the INSPIRA ART has not yet been tested or used in humans and the Company’s products have not been approved by the U.S. Food and Drug Administration (the “FDA”).

 

3. On July 16, 2021, the Company completed its IPO on the Nasdaq Capital Market, whereby the Company sold  i 2,909,091 ordinary shares, no par value (the “Ordinary Shares”) and  i 3,345,455 tradable warrants (inclusive of  i 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate proceeds received by the Company from the IPO were approximately  i 14,490, after deducting underwriting discounts and commissions and additional offering costs totaled in approximately  i 1,543. On July 16, 2021, following the closing of the IPO, the Company issued  i 2,113,905 Ordinary Shares and  i 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion of Company’s previously issued financial liabilities at fair value.

 

In October 2021, investors exercised  i 1,705,000 tradable warrants Company. The total proceeds received by the Company from this exercise were approximately  i 9,377. The Company paid fees of  i 7% in the amount of  i 656 according to the terms of a contract with a promoter in connection with the IPO for which the Company recorded a financial liability (note 8(3)).

 

4. The Company has not generated any revenue since its inception and the Company’s products are in the development stage. The Company’s operating loss for the years ended December 31, 2021 and 2022 were $ i 13.4 million and $ i 14.8 million, respectively and the Company’s net loss for the same period was $ i 16.9 million and $ i 10.3 million, respectively. As of December 31, 2022, the Company had an accumulated deficit of $ i 39.1 million. The Company funds its operations through the proceeds of the IPO.

 

The Company’s management intends to seek additional funding through public offerings, which will be utilized to fund product development and continue operations. The Company does not have any material financial obligations as of the balance date. The Company believes that it has sufficient resources to operate in the foreseeable future.

 

5.The Ukraine Conflict

 

Although we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations and future growth prospects in that region. As a result of the crisis in Ukraine, both the U.S. and other countries have implemented sanctions against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities, including the potential for increased tensions between Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against certain companies and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.

 

6.These financial statements were authorized by the board of directors on March 28, 2023.

 

F-10

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

 

New standards, interpretations and amendments not yet effective.

 

There are a number of standards, amendments to standards, and interpretations which have been issued by the IASB that are effective in future accounting periods that the Company has decided not to adopt early. 

  

In January 2020, the IASB issued amendments to IAS 1, which clarify the criteria used to determine whether liabilities are classified as current or non-current. These amendments clarify that current or non-current classification is based on whether an entity has a right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period. The amendments also clarify that ’settlement’ includes the transfer of cash, goods, services, or equity instruments unless the obligation to transfer equity instruments arises from a conversion feature classified as an equity instrument separately from the liability component of a compound financial instrument. The amendments were originally effective for annual reporting periods beginning on or after 1 January 2022. However, in May 2020, the effective date was deferred to annual reporting periods beginning on or after 1 January 2023.

 

In its June 2021 meeting, the IASB tentatively decided to amend the requirements of IAS 1 with respect to the classification of liabilities subject to conditions and disclosure of information about such conditions and to defer the effective date of the 2020 amendment by at least one year. 

 

The Company is currently assessing the impact of these new accounting standards and amendments. The Company will assess the impact of the final amendments to IAS 1 on classification of its liabilities once the those are issued by the IASB.

 

The Company does not believe that the amendments to IAS 1, in its present form, will have a significant impact on the classification of its liabilities.

 

The Company does not expect any other standards issued by the IASB, but not yet effective, to have a material impact on the Company.

 

 i 

Basis of preparation

 

 i 

Use of estimates and assumptions in the preparation of the financial statements

 

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. See also Note 3.

 

 i 

Cash and cash equivalents

 

Cash equivalents are considered by the Company to be highly-liquid investments, including, short-term deposits with banks, the maturity of which does not exceed three months at the time of deposit and which are not restricted.

 

F-11

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

 i 

Loss per share

 

Basic and diluted loss per share is calculated as net loss attributed to the Company, divided by the weighted average number of ordinary shares, adjusted for any bonus element.

 

Diluted (loss) earnings per share is determined by adjusting the earnings or loss attributable to common shareholders and the weighted average number of common shares outstanding for the effects of dilutive instruments, which includes stock options, as if their dilutive effect was at the beginning of the period. The calculation of the diluted number of common shares assumes that proceeds received from the exercise of “in-the- money” stock options and common share purchase warrants are used to purchase common shares of the Company at their average market price for the period.

 

In periods that the Company reports a net loss, any stock options or warrants outstanding are excluded from the calculation of diluted loss per share as their inclusion would be anti-dilutive.

 

 i 

Functional and foreign currency

 

The Company’s functional currency is NIS. However, the presentation currency is the U.S. dollar (“USD”). Transactions and balances are converted into USD in accordance with the principles set forth by International Accounting Standard (IAS) 21 “The Effects of Changes in Foreign Exchange Rates.” Accordingly, transactions and balances have been converted as follows:

 

  Assets and liability items were reported at closing rate of exchange at the statements of financial position date.

 

  Other comprehensive income items were reported at annual average rate of exchange at the statements of financial position date.

 

  Share capital, capital reserve and other capital movement items were at rate of exchange as of the date of recognition of those items.

 

  Accumulated deficit was based on the opening balance for the beginning of the reporting period in addition to the movements mentioned above.

 

  Rate of exchange rate differentials created was recognized in other comprehensive income and accumulated in equity.

 

 i 

Fair value measurement

 

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

 

A.In the principal market for the asset or liability, or

 

B.In the absence of a principal market, in the most advantageous market for the asset or liability.

 

The principal or the most advantageous market must be accessible by the Company in order to measure an asset or liability by its fair value.

 

F-12

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

 

When there are no quoted prices in active markets for identical assets or liabilities, the Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

 

Classification by fair value hierarchy Assets and liabilities measured in the statement of financial position at fair value are grouped into classes with similar characteristics using the following fair value hierarchy which is determined based on the source of input used in measuring fair value:

 

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.  

 

Level 2 - Inputs other than quoted prices included within Level 1 that are observable either directly or indirectly.

 

Level 3 - Inputs that are not based on observable market data (valuation techniques that use inputs that are not based on observable market data).

 

 i 

Financial instruments

 

1.Financial assets

 

The Company classifies its financial assets into the following category, based on the business model for managing the financial asset and its contractual cash flow characteristics. The Company’s accounting policy for the relevant category is as follows:

 

Amortized cost: other types of financial assets where the objective is to hold these assets in order to collect contractual cash flows and the contractual cash flows are solely payments of principal and interest. They are initially recognized at fair value including direct transaction costs and are subsequently carried at amortized cost using the effective interest rate method, less provision for impairment.

 

2.Financial Liabilities

 

The Company classifies its financial liabilities, including trade accounts payable and other accounts payable, which are initially recognized at fair value and subsequently carried at amortized cost using the effective interest method. The financial liabilities at fair value (see also Notes 8 and 19) are measured at fair value through profit or loss.

 

3. De-recognition

 

Financial assets - The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the rights to receive the contractual cash flows.

 

Financial Liabilities - The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire.

 

F-13

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

4. Impairment of financial assets

 

The Company does not have any assets which require a recognition of expected credit losses (“ECL”).

 

Cash and cash equivalents are subject to the impairment requirements of IFRS 9, the Company did not identify impairment for the cash and cash equivalent.

 

 i 

Property, plant, and equipment

 

Items of property, plant and equipment are initially recognized at cost including directly attributable costs. Depreciation is calculated on a straight-line basis, over the useful lives of the assets at annual rates as follows:

 

 i 
   Annual depreciation rate (%) 
     
Computers    i 33 
Development equipment    i 20 
Furniture and office equipment    i 6- i 15 
Leasehold Improvements    i 10 

 

 / 

Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to statement of the comprehensive loss during the reporting period in which they are incurred. The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is higher than its estimated recoverable amount.

 

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in statement of the comprehensive loss. 

 

 i 

Impairment of non-financial assets

 

Non-financial assets are subject to impairment test whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of the non-financial asset exceeds its recoverable amount (i.e., the higher of value in use and fair value less costs to dispose), the asset is written down and impairment charge is recognized accordingly.

 

Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset’s cash-generating unit (i.e., the smallest group of assets to which the asset belongs that generates cash inflow that is largely independent of cash inflows from other assets).

 

F-14

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

Impairment of non-financial assets (cont.)

 

An impairment loss allocated to an asset, is reversed only if there have been changes in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized.

 

Reversal of an impairment loss, as above, is limited to the lower of the carrying amount of the asset that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and the asset’s recoverable amount. After an impairment of non-financial asset is recognized, the Company examines at each reporting date whether there are indications that the impairment which was recognized in the past no longer exists or should be reduced. The reversal of impairment loss of an asset is recognized in statement of the comprehensive loss. Impairment charges are included in general and administrative expenses in the statement of the comprehensive loss. During the years ended December 31, 2022 and 2021, no impairment charges of non-financial assets were recognized.

 

 i 

Research and development costs

 

Expenditure on research activities is recognized in statement of the comprehensive loss as incurred. Development expenditures is recognized as an intangible asset when the Company can demonstrate:

 

The product is technically and commercially feasible.

 

The Company intends to complete the product so that it will be available for use or sale.

 

The Company has the ability to use the product or sell it.

 

The Company has the technical, financial and other resources to complete the development and to use or sell the product.

 

  The Company can demonstrate that the product will generate future economic benefits.

 

  The Company is able to measure reliably the expenditure attributable to the product during the development.

 

During the years ended December 31, 2021 and 2022, the Company’s research and development costs were not capitalized as they did not meet the criteria set forth in IAS 38.

 

 i 

Segment reporting

 

An operating segment is a component of the Company which fulfills the following criteria:

 

1.It is engaged in business operations from which it may derive income, and with respect to which it may bear expenses.

 

2.Its operating results are reviewed on a regular basis by the Company’s chief operational decision maker, in order to reach decisions regarding the resources allocated to it, and in order to assess its performance.

 

3.Separate financial information is available for the above.

 

The Company concluded that it has one operating segment. 

 

 i 

Share based payment

 

The Company measures the share based expense and the cost of equity-settled transactions with employees and service providers by reference to the fair value of the equity instruments at the date at which they are granted.

 

F-15

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

 i 

Options

 

The fair value is determined using an accepted options pricing model. The model is based on share price, grant date and on assumptions regarding expected volatility, expected life of the options, expected dividend, and a no risk interest rate. The options were granted before the Company became public and had no quoted price per share from a trading market.

 

The Company selected the Black-Scholes model as the Company’s option pricing model to estimate the fair value of the Company’s options awards. The option-pricing model requires a number of assumptions:

 

Expected dividend yield - The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has not historically paid cash dividends and has no foreseeable plans to pay cash dividends in the future.

 

Volatility - The expected volatility is based on similar companies’ stock volatility.

 

Risk free interest rate - The risk-free interest rate is based on the yield of governmental bonds with equivalent terms.

 

Contractual term - An option’s contractual term is the amount of time the holder has to exercise the option, per the contract.

 

 i 

Restricted Share Units (“RSUs”) - The fair value is measured by multiplying the number of the restricted shares units granted to employees, directors, and subcontractors by the quoted share price as of the grant date.

 

The granted options are settled in equity instruments and not in cash. The fair value of the options at the date of grant is charged to the statement of comprehensive loss over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to the statement of comprehensive loss over the remaining vesting period.

 

F-16

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

 i 

Government grants

 

The Israel Innovation Authority (“IIA”) provided government grants to the Company for certain research and development activities. The Company may be required to pay royalties to the IIA in the future if it generates sales from the related research and development activity. The grant was recognized as a liability in the financial statements. When the loan bears a below-market rate of interest, the liability is recognized at its fair value in accordance with the market interest rate prevailing at the time of receiving the grant. The difference between the consideration received and the liability recognized at inception was treated as a government grant and recognized as a reimbursement of research expenses. The repayment of the liability to the state is reviewed every reporting period, with changes in the liability resulting from a change in the expected royalties recognized in profit or loss.

 

 i 

Current taxes

 

The current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward losses.

 

 i 

Deferred tax

 

Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the estimated timing and level of future taxable profits together with future tax planning strategies. Deferred taxes are recognized in respect of temporary differences between the carrying amounts of assets and liabilities in the financial statements and the amounts attributable for tax purposes.

 

Deferred taxes are measured at the tax rates that are expected to apply in the period when the temporary differences are reversed based on tax laws that have been enacted or substantively enacted at the end of the reporting period. Deferred taxes are recognized in profit or loss, except when they relate to items recognized in other comprehensive income or directly in equity. Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. In addition, temporary differences (such as carry forward losses) for which deferred tax assets have not been recognized are reassessed and deferred tax assets are recognized to the extent that their recoverability is probable.

 

Any resulting reduction or reversal is recognized on “income tax” within the statement of comprehensive income. All deferred tax assets and liabilities are presented in the statement of financial position as non-current items, respectively. Deferred taxes are offset in the statement of financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority.

 

F-17

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):

 

 i 

Employee benefits

 

The Company has several employee benefit plans for Israeli employees:

 

1.Short-term employee benefits: Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions, which are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made.

 

2.Post-employment benefits: The plans are normally financed by contributions to insurance companies and classified as defined contribution plans. The Company has contributed for all of its employees’ contribution plans pursuant to Section 14 to the Severance Pay Law since 2018 under which the Company pays fixed contributions and will not have any legal or constructive obligation to pay further contributions if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in the current and prior periods.

 

 i 

NOTE 3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS:

 

Share based payments

 

The fair value of share options was estimated by using a Black Scholes model approach, which was aimed to model the value of the Company’s equity over time. A change of the estimation can cause to recognition or reversal of share based compensation expenses.

 

Financial liabilities at fair value

 

The fair value of financial liabilities at fair value was estimated by using a Black Scholes model and Monte-Carlo simulation approach, which was aimed to model the value of the Company’s assets over time. The simulation approach was designed to take into account the terms and conditions financial liability, which are described in Note 8 and Note 20, as well as the capital structure of the Company and the volatility of its assets. The valuation was performed based on management’s assumptions and projections.

 

Determination of lease incremental borrowing rate

 

The Company measures the incremental borrowing rate by analyzing similar borrowing that could be obtained from an independent valuation under comparable terms and conditions. A change of the estimation can cause to an increase or decrease in the measurement of a right-of-use asset and lease liability.

 

 i 

NOTE 4 – DEPOSITS

 

The deposits are three short-term bank deposits with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.

 

On May 10, 2022, the Company deposited  i 2,000 with an annual interest rate of  i 3.02% for a period of 9 months. As of December 31, 2022, the value of the deposit is  i 2,039.

 

On August 11, 2022, the Company deposited  i 2,000 with an annual interest rate of  i 4.39% for a period of 12 months. As of December 31, 2022, the value of the deposit is  i 2,034.

 

On August 24, 2022, the Company deposited  i 3,000 with an annual interest rate of  i 4.47% for a period of 9 months. As of December 31, 2022, the value of the deposit is  i 3,047.

 

As of December 31, 2022 total deposits amounted to  i 7,120.

 

 i 

NOTE 5 - OTHER CURRENT ASSETS:

 

 i 
   December 31,
2022
   December 31,
2021
 
         
Prepaid expenses    i 256     i 426 
Institutions    i 276     i 210 
Restricted Cash    i 56     i 120 
Others    i 3     i 3 
Total    i 591     i 759 
 / 

 

F-18

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 6 - PROPERTY AND EQUIPMENT, NET:

 

For the year ended December 31, 2022:

 

 i 
   Computers   Leasehold
improvements
   Development
equipment
   Furniture
and office
equipment
   Total 
Cost                    
At January 1, 2022    i 84     i 7     i 64     i 81     i 236 
Additions    i 43     i 30     i 191     i 40     i 304 
Exchange rate deference   ( i 6)   ( i 4)   ( i 26)   ( i 5)   ( i 41)
                          
At December 31, 2022    i 121     i 33     i 229     i 116     i 499 
Accumulated depreciation                         
At January 1, 2022    i 22     i 1     i 8     i 3     i 34 
Depreciation    i 33     i 3     i 19     i 6     i 61 
Exchange rate deference   ( i 4)   -    ( i 2)   ( i 1)   ( i 7)
                          
At December 31, 2022    i 51     i 4     i 25     i 8     i 88 
Net book value:                         
As of December 31, 2022    i 70     i 29     i 204     i 108     i 411 

 

 / 
*Less than thousand dollars

 

For the year ended December 31, 2021:

 

   Computers   Leasehold
improvements
   Development
equipment
   Furniture
and office
equipment
   Total 
Cost                    
At January 1, 2021    i 22             i 7          i 6     i 19     i 54 
Additions    i 62     i 0     i 58     i 62     i 182 
                          
At December 31, 2021    i 84     i 7     i 64     i 81     i 236 
                          
Accumulated depreciation                         
                          
At January 1, 2021    i 7    *     i 1     i 1     i 9 
Depreciation    i 15     i 1     i 7     i 2     i 25 
                          
At December 31, 2021    i 22     i 1     i 8     i 3     i 34 
Net book value:                         
As of December 31, 2021    i 62     i 6     i 56     i 78     i 202 

 

*Less than one thousand dollars

 

F-19

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 7 - OTHER ACCOUNTS PAYABLE:

 

 i 
   December 31,
2022
   December 31,
2021
 
         
Employees salaries and related liabilities    i 396     i 339 
Related parties    i 332     i 275 
Accrued expenses    i 470     i 82 
Other    i 19     i 29 
Total    i 1,217     i 725 
 / 

 

 i 

NOTE 8 - LIABILITY IN RESPECT OF GOVERNMENT GRANTS:

 

The Company received the approval of the IIA for its participation in certain development expenses carried out by the Company, within the framework of determined budgets and time periods. The total amount the Company received during 2020 and 2021 was  i  i 800 /  (NIS  i  i 2,722,628 / ).

 

In accordance with its commitment, the Company is obliged to pay the IIA royalties of  i 3% of sales, constituting the revenues derived from sales of the Company’s ART system that was financed by the IIA, up to the total amount of the grant actually received, all linked to the exchange rate of the USD and bears an annual interest linked to the LIBOR. Therefore, the total amount of the grants that will be repaid through royalties and will increase until repayments begin.

 

The difference between the consideration received and the liability recognized at inception (present value) was treated as a government grant according to IAS 20 and recognized as a reimbursement of research expenses.

 

 i 
   December 31,
2022
   December 31,
2021
 
         
At January 1, 2022    i 302     i 372 
Amounts received during the year, non- capitalized   
-
     i 107 
Exchange rate differences   ( i 41)    i 10 
Amounts recognized as an offset from research and development expenses   
-
    ( i 255)
Revaluation of the liability    i 137     i 68 
As of December 31, 2022    i 398     i 302 
 / 

 

F-20

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 9 - FINACIAL LIABILITIES AT FAIR VALUE:

 

 i 
  

December 31,

2022

   December 31,
2021
 
         
Non-tradable warrants (1)    i 3     i 196 
Non-tradable warrants, SAFE and CLA (2)    i 35     i 1,393 
Tradable warrants (3)    i 304     i 1,493 
Financial liability (4)    i 26     i 133 
Total    i 368     i 3,215 

 

 / 
1.Non Tradable Warrants

 

As part of an agreement signed in 2019, the convertible loan investors received, upon conversion in 2020  i 756,333 Ordinary Shares and non-tradable warrants to purchase an additional  i 169,019 ordinary shares upon consummation of an IPO on the Nasdaq. The warrants will be converted into Ordinary Shares of the Company at an exercise price equal to the initial public offering price which was $ i 5.5 and are exercisable for three years after the IPO.

 

The warrants were designated to be measured at fair value through profit or loss.

 

On July 2021, as part of the IPO, the investors received the specified warrants. As of December 31, 2022 the fair value of the warrants was  i 3.

 

2.Non-tradable warrants, SAFE and Convertible Loan Investors

 

On July 16, 2021, following the IPO, the Company issued  i 2,113,905 Ordinary Shares,  i 1,149,582 non-tradable warrants to investors and  i 16,587 non-tradeable warrants to brokers in connection with the conversion of Company’s convertible loan and SAFE according to its terms. The fair value of the shares was classified as equity with total value of  i 10,041 at the conversion date. The non-tradable warrants were designated to be measured at fair value through profit or loss.

 

The non-tradable warrants fair value as of December 31, 2022 is  i 35.

 

3.Tradable warrants

 

The Company sold  i 3,345,455 tradable warrants in the IPO.  i The tradable warrants have an exercise price of $5.5 and they are exercisable for five years after the initial public offering date. In October 2021, investors exercised  i 1,705,000 tradable warrants whereby the Company issued  i 1,705,000 Ordinary Shares to such investors. The total proceeds received by the Company from this exercise were approximately  i 9,377. The net proceeds after fees deducting were approximately  i 8,721.

 

As of December 31, 2022, the Company has  i 1,640,455 tradable warrants.

 

The tradable warrants were designated to be measured at fair value through profit or loss.

 

The tradable warrants fair value as of December 31, 2022 is  i 304.

 

  4. Financial Liability

 

Financial liability to pay  i 7% fees on the fundings that will be received from exercises of tradable warrants.

 

Financial liability was designated to be measured at fair value through profit or loss.

 

The Financial liability fair value as of December 31, 2022 is  i 26.

 

F-21

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 10 - EQUITY (DEFICT):

 

A. Share capital:

 

 i 
   Number of shares as of   Number of shares as of 
   December 31, 2022   December 31, 2021 
   Authorized   Issued and outstanding   Authorized   Issued and outstanding 
Ordinary shares    i 100,000,000     i 11,338,940     i 100,000,000     i 10,091,706 

 

 / 

Since the Company’s incorporation in February 2018 and before the IPO, the Company issued the following Ordinary Shares: (i) an aggregate of  i 27,566 Ordinary Shares for no consideration to the Company’s founders and certain advisors; (ii)  i 1,877,196 Ordinary Shares as bonus shares for no consideration to existing shareholders; (iii) an aggregate of  i 756,333 Ordinary Shares investors. See Note 8(1).

 

On March 18, 2021, the Company’s shareholders approved a  i 12.5 to  i 1 reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation is NIS  i 310,000,000 divided into  i 24,800,000 Ordinary Shares.

 

On June 1, 2021, the Company’s shareholders approved an amendment to the structure of the Company’s share capital (both authorized and issued) by cancelling the par value in addition to implementing an additional reverse split at a ratio of  i 2.94 to  i 1, pursuant to which holders of our Ordinary Shares received one Ordinary Share for every 2.94 Ordinary Shares held.

 

On June 1, 2021, the Company’s shareholders approved an amendment to the structure of the Company’s share capital (both authorized and issued) by cancelling the par value of the Company’s shares such that each Ordinary Share with par value of NIS  i 0.125 will become one Ordinary Share with no par value. The authorized share capital of the Company following the reverse stock split is NIS  i 310,000,000 divided into  i 8,435,375 Ordinary Shares, with no par value.

 

On June 1, 2021, the Company’s shareholders approved an increase in the authorized share capital of the Company to  i 15,000,000 Ordinary Shares of no par value.

 

On July 16, 2021, the Company completed its IPO on Nasdaq Capital Market whereby the Company sold  i 2,909,091 Ordinary Shares and  i 3,345,455 tradable warrants (inclusive of  i 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters).

 

Following the IPO, the Company issued  i 2,113,905 Ordinary Shares and  i 1,149,582 non-tradable warrants to investors and  i 16,587 non-tradeable warrants to brokers in connection with the conversion of Company’s previously issued financial liabilities, see note 8(2).

 

The aggregate proceeds received by the Company from the IPO were approximately  i 14,490, after deducting underwriting discounts and commissions and additional offering direct costs totaled in approximately  i 1,543. The gross proceeds were  i 16,033.

 

 i 

Total non-cash direct expenses in IPO were as following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled 589; (ii) The Company issued 145,455 non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal to 125% of the initial public offering price and be exercisable for three years after the initial public offering. As of the date of the IPO, the tradable warrants fair value was 264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise of tradable warrants. The payment was measured according to IFRS 2 at the grant date. As of the IPO date, the fair value of the financial liability was 310.

 

Total non-cash expenses were  i 1,163.

 

F-22

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 10 - EQUITY (DEFICT) (CONT.):

 

In addition, the Company had non-direct expenses as following: (i) cash expenses amounted to  i 722 and (i) non-cash expenses amounted to  i 123 ( i 22,382 Ordinary Shares issued to service providers).

 

Total IPO expanse direct and non direct, cash and non-cash were:  i 3,551.

 

Total IPO expenses allocated to the profit and loss were  i 1,265. Total IPO expenses deducted from the equity were  i 2,286.

 

During the year 2021 the Company issued an aggregate amount of  i 655,601 Ordinary Shares in connection to vested RSUs and additional  i 24,631 Ordinary Shares in connection to options exercise.

 

On December 17, 2021, the Company’s shareholders approved an increase in the authorized share capital of the Company to  i 100,000,000 Ordinary Shares of no-par value.

 

During the year ended December 31 2022, the Company issued an aggregate amount of  i 1,240,204 Ordinary Shares in connection to vested RSUs and an additional  i 7,030 Ordinary Shares in connection to option exercises.

 

B. Loss per share:

 

Loss per share has been calculated using the weighted average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit for the period as follows:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Loss for the period    i 10,273     i 16,955     i 7,228 
Total number of Ordinary Shares    i 11,338,940     i 10,091,706     i 2,661,095 
Weighted average number of Ordinary Shares    i 10,794,594     i 5,306,225     i 1,967,790 
                
Basic and diluted loss per share
   ( i 0.95)   ( i 3.2)   ( i 3.67)
 / 

 

 i 

NOTE 11 - RESEARCH AND DEVELOPMENT EXPENSES:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Share based payment    i 2,311     i 1,768     i 2,230 
Salary and related expenses    i 3,332     i 1,533     i 1,237 
Subcontractors    i 929     i 496     i 125 
Materials and related expenses    i 1,094     i 204     i 440 
Depreciation    i 238     i 134     i 196 
IIA participation   -    ( i 255)   ( i 383)
Other    i 150     i 29     i 28 
Total    i 8,054     i 3,909     i 3,873 
 / 

 

F-23

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 12 - SALES AND MARKETING EXPENSES:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Share based payment    i 501     i 1,186    
     -
 
Salary and related expenses    i 287     i 220    
-
 
Professionals’ fees    i 521     i 520    
-
 
Other    i 16     i 25    
-
 
     i 1,325     i 1,951    
-
 
 / 

 

 i 

NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Share based payment    i 1,093     i 2,581     i 818 
Professional fees    i 1,522     i 1,390     i 154 
Related NASDAQ IPO expenses   
-
     i 1,265     i 1,235 
Director’s fees and share based compensation    i 1,113     i 1,142    
-
 
Salary and related expenses    i 723     i 545     i 140 
Insurance expenses    i 565     i 363    
-
 
Office maintenance    i 103     i 91     i 77 
Depreciation    i 123     i 84     i 7 
Travel abroad    i 106     i 65     i 12 
Others    i 43     i 46     i 4 
Total    i 5,391     i 7,572     i 2,447 
 / 

 

F-24

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 14 – FINANCIAL (INCOME) AND EXPENSES:

 

 i 
Income  Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Revaluation of financial liabilities at fair value through profit or loss   ( i 2,592)   
-
    
     -
 
Foreign currency transaction income   ( i 1,774)   
-
    
-
 
Interest on deposits   ( i 308)   ( i 1)   
-
 
Others   ( i 4)   
-
    
-
 
Total   ( i 4,678)   ( i 1)   
-
 

 

 / 
 i 
Expenses  Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Revaluation of financial liabilities at fair value through profit or loss   
-
     i 2,183     i 893 
Foreign currency transaction loss, net   
-
     i 1,186    - 
Revaluation of liability in respect of government grants    i 138     i 69     i 40 
Finance expense in respect of lease liability    i 37     i 6     i 5 
Others    i 6     i 80     i 21 
Total    i 181     i 3,524     i 959 
 / 

 

 i 

NOTE 15 - TAXES ON INCOME:

 

Taxes on income:

 

Israeli corporate tax rate was  i  i 23 / % in 2022 and 2021.

 

Net operating losses carry forwards:

 

As of December 31, 2022, the Company has carried forward tax losses of approximately  i 11,540, which may be carried forward and offset against taxable income for an indefinite period in the future. The Company did not recognize deferred tax assets relating to carry forward losses in the financial statements because their utilization in the foreseeable future is not probable. As of December 31, 2022, the Company has temporary differences of  i 2,838 for which no deferred tax asset was recognized.

 

Theoretical tax:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Loss before taxation   ( i 10,273)   ( i 16,955)   ( i 7,228)
Theoretical tax credit at applicable statutory rate:  i  i 23 / %   ( i 2,363)   ( i 3,900)   ( i 1,662)
Non-allowable expenses   ( i 1,804)   ( i 2,070)    i 4,733 
Temporary differences and tax losses for which no Deferred Tax Asset is recognized   ( i 559)   ( i 1,830)   ( i 3,071)
Income tax benefit   
-
    
-
    
-
 
 / 

 

F-25

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 16 - LEASES:

 

The Company has lease contracts for office facilities and vehicles used in its operations. Leases of vehicles generally have lease terms up to  i three years.

 

The Company leases vehicles for three-year periods from several different leasing companies and from time to time changes the number of leased vehicles according to its current needs. The leased vehicles are used by the Company’s management, and other employees whose employment agreements include an obligation of the Company to put a vehicle at their disposal. The Company accounted for the arrangement between it and the leasing companies as a lease arrangement in the scope of IFRS 16 and for the arrangement between it and its employees as an arrangement in the scope of IAS 19, Employee Benefits. The agreements with the leasing companies do not contain extension and/or termination options that the Company is reasonably certain to exercise.

 

A lease liability in the amount of  i 281 and right-of-use asset in the amount of  i 345 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of vehicles.

 

 i 

The Company leases offices in Ra’anana are for a period of 69 months. The contractual period of the aforesaid lease agreement ends in August 2027. The Company has an option to terminate the contract after 45 months with a penalty in amount of NIS 500,000 that will be diminish in NIS 30,000 in each month from the 45th month of the contract. The Company does not currently expect to exercise the termination option in the lease agreement.

 

A lease liability in the amount of  i 776 and right-of-use asset in the amount of  i 762 have been recognized in the statement of financial position as of December 31, 2022 in respect of leases of offices.

 

Set out below are the carrying amounts of right-of-use assets recognized and the movements during the period:

 

 i 
   Office facility   Vehicles   Total 
At January 1, 2022    i 1,047     i 113     i 1,160 
Additions   
-
     i 416     i 416 
Exchange rate differences   ( i 114)   ( i 26)   ( i 140)
Disposals   
-
    ( i 29)   ( i 29)
Depreciation expense   ( i 171)   ( i 129)   ( i 300)
As of December 31, 2022    i 762     i 345     i 1,107 

  

 / 

Set out below are the carrying amounts of lease liabilities and the movements during the period:

 

 i 
   2022   2021   2020 
At January 1, 2022    i 1,181     i 275     i 153 
Additions    i 367     i 1,176     i 273 
Accretion of interest   
-
    
-
     i 5 
Financial expenses    i 24    
-
    ( i 5)
Exchange rate differences   ( i 138)    i 43     i 20 
Disposals   ( i 27)   ( i 99)   
-
 
Payment   ( i 350)   ( i 214)   ( i 171)
As of December 31, 2022    i 1,057     i 1,181     i 275 

 

 / 

F-26

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 16 - LEASES (CONT.):

 

The following are the amounts recognized in profit or loss:

 

 i 
   Year ended
December 31,
2022
   Year ended
December 31,
2021
   Year ended
December 31,
2020
 
             
Depreciation expense of right-of-use assets    i 300     i 196     i 196 
Interest expense on lease liabilities   
-
    
-
     i 5 
Total amount recognized in profit or loss    i 300     i 196     i 201 

 

 / 

The Company had total cash outflows for leases of  i 350 in 2022 and  i 214 in 2021. The Company also had non-cash additions to right-of-use assets and lease liabilities of  i 416 in 2022 and  i 1,176 in 2021.

 

 i 

NOTE 17 - SHARE BASED PAYMENT:

 

In December 2019, the Company established a share option plan (the “Plan”). Under the Plan, total of  i 602,989 options were granted until December 31, 2022. As of December 31, 2022, a total of  i 500,772 options to subscribe Ordinary Shares that have been granted to employees, consultants and directors are outstanding.
A total of  i 3,707,542 RSUs that have been granted to employees, consultants and directors,  i 1,895,808 RSUs are vested as of December 31, 2022.

 

On April 20, 2020 a total of  i 478,747 options to subscribe Ordinary Shares have been granted to employees and consultants.  i The exercise price per share to 123,719 and 355,029 options was USD 0.0029 (AUD 0.052) and USD 2.67 (AUD 4.2), respectively. The vesting period is up to 3 years from the grant date, according to the various vesting periods: from an immediate one and up to 3 years. Contractual life of the options under the Plan is 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay 25% of capital gain tax upon exercise.  In October 2020, 73,380 options were canceled.

 

On December 17, 2020, the Israeli Taxes Authority (ITA) approved a ruling request from the Company for a tax-free amendment of the commercial terms of the outstanding options, including (i) a reduction of the exercise price to NIS  i 0.37 per share, and (ii) a shortening of the vesting schedules.

 

The Company implemented IFRS 2-Share based payment on options terms change.

 

On December 20, 2020, the board of directors granted a total of  i 56,653 options to subscribe Ordinary Shares to employees and consultants. The vesting period is up to  i 3 years from the grant date. The exercise price per share was NIS  i 0.37.

 

Contractual life of the options under the Plan is  i 10 years. The options were granted under section 102 of the Israeli Tax Ordinance which enables the employee to pay  i 25% of capital gain tax upon exercise.

 

On February 21, 2021,  i the Company’s board of directors approved a grant of 13,605 non-tradable shares options which are exercisable to 13,605 Ordinary shares to employees and a total of 21,768 share options which are exercisable to 21,768 Ordinary Shares to consultants. The vesting period is three years commencing on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years. The options to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

 

F-27

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 17 - SHARE BASED PAYMENT (CONT.):

 

On March 16, 2021, the Company’s board of directors approved a grant of  i 81,633 non-tradable shares options to a director, which are exercisable to  i 81,633 Ordinary Shares. The share options vesting period is up to  i three years from the grant date. The exercise price per share was NIS 0.37 ($ i 0.12). The contractual life of the options under the Plan is  i ten years. The options were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a  i 25% capital gain tax upon exercise.

 

On August 12, 2021, the Company’s board of directors resolved to increase the pool of options available under the Plan to  i 25% of the Company’s equity, on a fully diluted basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the Plan was  i 4,180,898.

 

On November 2, 2021, the Company’s board of directors approved a grant of  i 2,658,188 RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest over a period of  i three years. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a  i 25% capital gain tax upon exercise.

 

On November 2, 2021, the Company’s board of directors approved a grant of  i 10,000 RSUs to the Company’s advisory board. The RSUs represents the right to receive Ordinary Shares at a future time and vest over a period of  i three years.

 

On March 24, 2022,  i the Company’s board of directors approved a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company’s advisory board members and an additional consultant. The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

 

On March 24, 2022,  i the Company’s board of directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares. The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual life of the options under the Plan is ten years.

 

On April 6, 2022,  i the Company’s board of directors approved a grant of 285,713 fully vested RSUs to an officer. The RSUs represent the right to receive Ordinary Shares. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

 

On May 19, 2022,  i the Company’s board of directors approved a grant of 30,000 RSUs to an employee. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

 

On November 22, 2022,  i the Company’s board of directors approved a grant of 165,000 RSUs to employees. The RSUs represent the right to receive Ordinary Shares at a future time and vest over a period of three years, with a 1-year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.

 

F-28

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 17 - SHARE BASED PAYMENT (CONT.):

 

 i 

The fair value of all granted options was estimated by using the Black Scholes model, which was aimed to model the value of the Company’s assets over time. The simulation approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:

 

(i)The expected volatility is between 50%-52.4%

 

(ii)The dividend rate 0%; and

 

(iii)Expected term – three years.

 

The valuation was completed with the assistance of an independent valuator based on management’s assumptions.

 

During the year ended December 31, 2022, the Company recorded share based payment expenses to employees, directors and subcontractors in the amount of  i 4,879.

 

 The options to services providers and advisers outstanding as of December 31, 2022, as follows:

 

 i 
   Year ended
December 31, 2022
 
   Number of
options
   Weighted
average
Exercise
price NIS
 
         
Outstanding at beginning of year    i 87,833     i 0.37 
Granted    i 29,400     i 10.84 
Exercised   ( i 2,721)    i 0.37 
Forfeited   
-
    
-
 
Outstanding as of December 31, 2022    i 114,512     i 3.058 
Exercisable options    i 82,257     i 0.71 

 

 / 

During the year ended December 31, 2022, the Company recorded share based payment expenses of option to services providers and advisers in the amount of  i 54.

 

The RSUs to services providers and advisers outstanding as of December 31, 2022 as follows:

 i 
   Number of RSUs 
Outstanding at beginning of year    i 10,000 
Granted    i 22,500 
Vested   ( i 14,234)
Outstanding as of December 31, 2022    i 18,266 
Vested as of December 31, 2022    i 14,234 

 

 / 

F-29

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 17 - SHARE BASED PAYMENT (CONT.):

 

During the year ended December 31, 2022, the Company recorded share based payment expenses of RSUs to services providers and advisers in the amount of  i 33.

 

The options to employees and directors outstanding as of December 31, 2022, as follows:

 

    Year ended
December 31, 2022
 
    Number of options     Weighted average Exercise price NIS  
             
Outstanding at beginning of year      i 448,120        i 0.37  
Exercised      i 4,309        i 0.37  
Forfeited     ( i 57,551 )      i 0.37  
Outstanding as of December 31, 2022      i 386,260        i 0.37  
Exercisable options      i 342,757        i 0.37  

 

During the year ended December 31, 2022, the Company recorded share based payment expenses of options to employees and directors in the amount of  i 174

 

The RSUs to employees and directors outstanding as of December 31, 2022, as follows:

 

   Number of RSUs 
Outstanding at beginning of year    i 2,002,587 
Granted    i 1,016,854 
Forfeited   ( i 65,626)
Vested   ( i 1,225,973)
Outstanding as of December 31, 2022    i 1,727,842 
Vested as of December 31, 2022    i 1,881,574 

 

During the year ended December 31, 2022, the Company recorded share based payment expenses of RSUs to employees and directors in the amount of  i 4,618.

 

F-30

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 17 - SHARE BASED PAYMENT (CONT.):

 

The options to services providers and advisers outstanding as of December 31, 2021, as follows:

   Year ended
December 31, 2021
 
   Number of
options
   Weighted
average
Exercise
price NIS
 
         
Outstanding at beginning of year    i 165,987     i 0.37 
Reclassified to employees and directors   ( i 71,260)    i 0.37 
Granted    i 16,326     i 0.37 
Exercised   ( i 20,086)    i 0.37 
Forfeited   ( i 3,134)    i 0.37 
Outstanding as of December 31, 2021    i 87,833     i 0.37 
Exercisable options    i 62,715     i 0.37 

  

The RSUs to services providers and advisers outstanding as of December 31, 2021, as follows:

   Number of RSUs 
Outstanding at beginning of year   
-
 
Granted    i 10,000 
Outstanding as of December 31, 2021    i 10,000 
Exercisable RSUs   
-
 

 

The options to employees and directors outstanding as of December 31, 2021, as follows:

 

   Year ended
December 31, 2021
 
   Number of options   Weighted average Exercise price NIS 
         
Outstanding at beginning of year    i 296,038     i 0.37 
Reclassified to employees and directors    i 71,260     i 0.37 
Granted    i 95,238     i 0.37 
Exercised   ( i 4,544)    i 0.37 
Forfeited   ( i 9,872)    i 0.37 
Outstanding as of December 31, 2021    i 448,120     i 0.37 
Exercisable options    i 347,069     i 0.37 

 

The restricted shares units to employees and directors outstanding as of December 31, 2021, as follows:

 

   Number of RSUs 
Outstanding at beginning of year   
-
 
Granted    i 2,658,188 
Vested   ( i 655,601)
Outstanding as of December 31, 2021    i 2,002,587 

 

F-31

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 18 - RELATED PARTIES:

 

The following transactions arose with related parties:

 

Transactions and balances with related parties:

 

1.Shareholders and other related parties’ benefits

 

 i 
   December 31,
2022
   December 31,
2021
   December 31,
2020
 
Salary and related expenses – officers and directors    i 1,923     i 1,042     i 795 
Share based payment – officers and directors    i 3,745     i 5,876     i 1,805 

 

 / 
2.Balances with related parties

 

 i 
Name  Nature of transaction  December 31,
2022
   December 31,
2021
 
Officers   i Salaries and related    i (292)    i (317)
Directors   i Compensation for directors    i (40)    i (57)
 / 

 

 i 

NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT:

 

The Company is exposed to a variety of financial risks, which result from its financing, operating and investing activities. The objective of financial risk management is to contain, where appropriate, exposures in these financial risks to limit any negative impact on the Company’s financial performance and position. The Company’s financial instruments are its cash and other current assets, convertible loan, payables and other payables. The main purpose of these financial instruments is to raise finance for the Company’s operation. The Company actively measures, monitors, and manages its financial risk exposures by various functions pursuant to the segregation of duties and principals. The risks arising from the Company’s financial instruments are mainly credit risk and currency risk. The risk management policies employed by the Company to manage these risks are discussed below.

 

Credit risk

 

Credit risk arises when a failure by counterparties to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the balance sheet date. The Company closely monitors the activities of its counterparties and controls the access to its intellectual property which enables it to ensure the prompt collection. The Company’s main financial assets are cash and cash equivalents and deposits represent the Company’s maximum exposure to credit risk in connection with its financial assets. Wherever possible and commercially practical, the Company holds cash with major financial institutions in Israel.

 

F-32

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):

 

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

 

 i 
   December 31,
2022
   December 31,
2021
 
Cash and cash equivalents    i 6,783     i 23,749 
Deposits    i 7,120    
-
 
Other current assets (Restricted deposits)    i 56     i 120 
Total    i 13,959     i 23,869 

 

 / 

Currency risk

 

Currency risk is the risk that the value of financial instruments will fluctuate due to changes in foreign exchange rates. Currency risk arises when future commercial transactions and recognized assets and liabilities are denominated in a currency that is not the Company’s functional currency. The Company exposed to foreign exchange risk arising from currency exposure primarily with respect to the USD. The Company’s policy is not to enter into any currency hedging transactions.

 

The carrying amounts of the Company’s foreign currency denominated monetary liability at the reporting date are as follows:

 

 i 
   December 31,
2022
   December 31,
2021
 
Assets        
Cash and cash equivalents    i 3,766     i 19,391 
Deposits    i 7,120    
-
 
     i 10,886     i 19,391 
           
Liabilities          
Financial liabilities    i 368     i 3,215 
Total    i 368     i 3,215 
Net    i 10,518     i 16,176 

 

 / 

Sensitivity analysis

 

A  i 10% strengthening of the NIS against the following currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. For a  i 10% weakening of the NIS against the relevant currency, there would be an equal and opposite impact on the profit and other equity.

 

 i 
   Year ended
December 31,
   Year ended
December 31,
 
   2022   2021 
USD    i 1,051     i 1,617 
AUD    i 10     i 205 
GB Pound    i 45     i 53 

 

 / 

F-33

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 19 - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONT.):

 

Liquidity risks:

 

Liquidity risk is the risk that arises when the maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also increase the risk of loss. The Company has procedures to minimize such loss by maintaining sufficient cash and other highly liquid current assets and by having available an adequate amount of committed credit facilities. As of the balance sheet date, the Company has a negative working capital.

 

The following tables detail the Company’s remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay.

 

 

As of December 31, 2022:

 

 i 
   Up to
1 year
   Between
1 and 3
years
   More than
3 years
 
             
Other payables    i 719    
-
    
-
 
Lease liabilities    i 381     i 635     i 374 
Trade payables    i 150    
-
    
-
 
Loan from the IIA   
-
     i 24     i 776 
Total    i 1,250     i 659     i 1,150 

 

 / 

As of December 31, 2021:

 

   Up to
1 year
   Between
1 and 3
years
   More than
3 years
 
             
Other payables    i 611    
-
    
-
 
Lease liabilities    i 305     i 537     i 678 
Trade payables    i 93    
-
    
-
 
Loan from the IIA   
-
     i 7     i 868 
Total    i 1,009     i 544     i 1,546 

 

F-34

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 20 - COMMITMENTS AND CONTINGENCIES

 

Commitments

 

1.The Company has a bank guarantee in the amount of 63 for the offices it rents. In accordance with the guarantee, the Company has a pledged deposit in the same amount as of December 31, 2022.

 

2.

In July 2022, the Company entered into an agreement with a contractor for the development of the HYLA™ blood sensor. Total payment agreed in the contract is 710. According to the agreement with the developer, the development cost will be paid in a few tranches considering the development lifecycle, which was defined as five phases for each of the blood parameters to be measured by the sensor.

 

The Company is entitled to terminate the contract upon reaching the third phase.

 

3.As of December 31, 2022, part of the development outputs reached the second phase and part are on the third phase. Approximately half of the contract total amount was recorded as development expenses as of December 31, 2022. An amount of  i 75 was paid as prepayment.

 

Contingencies

 

1.In the normal course of business, various legal claims and other contingent matters may arise. Management believes that any liability that may arise from such matters would not have a material adverse effect on the Company’s results of operations or financial condition as of and for the years ended December 31, 2022, and 2021.

 

2.On March 4, 2022, Exchange Listing, LLC, or Exchange, filed a complaint in the Federal Court for the Southern District of New York against us in connection with a contract between the parties. The contract related to certain consulting services provided to us by Exchange in preparation for our initial public offering.The complaint is against us and, and the Company president and former Chief Financial Officer, Joe Hayon, in connection with a contract between the parties pursuant to which Exchange provided certain consultancy services to us in preparation for our initial public offering. The precise damages sought are unclear, however Exchange is seeking approximately  i 250,000 plus  i 75,000 Ordinary Shares or the cash equivalent. As of the date of this annual report, we have not been formally served with the complaint. On July 1, 2022, the Company filed a motion to dismiss for failure to state a claim upon relief can be granted based on the language of the written contract between the parties. On March 8, 2023, the court issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims against Joe Hayon and he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the extent it was based improper termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement), Count VI (Breach of Implied Covenant of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written agreement based on alleged anticipatory repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to the extent based on alleged oral agreement) and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early dismissal stage. The Company will continue to defend itself vigorously with respect to this matter.

 

3.

On November 9, 2022, the Company received notice of a complaint filed by Udi Nussinovitch, the Registrant’s former Chief Scientific Officer, in Tel-Aviv District Court, as well as a complaint filed with the regional labor court in Tel Aviv on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Company’s Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr. Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. Previously, on February 24, 2022, the Company filed a claim against Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company.

 

As of the balance date, the Company believes that the claims will result in no payments by the Company.

 

F-35

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

 i 

NOTE 21 - FAIR VALUE MEASUREMENT:

 

Fair value hierarchy

 

The following tables detail the Company’s assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

 

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

 

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level 3: Unobservable inputs for the asset or liability.

 

As of December 31, 2022:

 

 i 
   Level 1   Level 2   Level 3 
Non-tradable Warrants   
     -
     i 3    
     -
 
Non-tradable warrants of SAFE and Convertible Loan investors   
 
     i 35    
 
 
Financial liability   
-
     i 26    
-
 
Tradable warrants    i 304    
-
    
-
 
Total    i 304     i 64    
-
 

 

 / 

As of December 31, 2021:

 

   Level 1   Level 2   Level 3 
Non-tradable Warrants   
     -
     i 196    
     -
 
Non-tradable warrants of SAFE and Convertible Loan investors   
 
     i 1,393    
 
 
Financial liability   
-
     i 133    
-
 
Tradable warrants    i 1,493    
-
    
-
 
Total    i 1,493     i 1,722    
-
 

 

As of December 31, 2022, the fair value measurement of the warrant’s securities in the table above, was estimated using the Black Scholes model, based on assumptions for the variables that are required as of the warrants’ valuation date.

 

 i 

The key inputs that were used in the both items of non-tradable warrants valuation were: risk-free interest rate between  i 5.04% and  i 5.26%, expected volatility between  i 56.5%- i 57.8% , expected dividend yield of  i 0% and expected term of warrants of  i 1.54-2.54 years.

 

 / 

F-36

 

 

INSPIRA TECHNOLOGIES OXY B.H.N. LTD.

NOTES TO FINANCIAL STATEMENTS

(U.S. dollars in thousands)

 

NOTE 21 - FAIR VALUE MEASUREMENT (Cont.):

 

As of December 31, 2021, the fair value measurement of the SAFE and the warrant’s securities in the table above, was estimated using the Black Scholes model, based on a variety of significant unobservable inputs a thus represent a level 2 measurement within the fair value hierarchy.

 

The key inputs that were used in both items of non-tradable warrants valuation were: risk-free interest rate between  i 0.19% and  i 0.73%, expected volatility between  i 55.3%- i 57.8%, expected dividend yield of  i 0% and expected term of warrants of  i 2.54-3. i 54 years.

 

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

 

Movements in level 2 liability during 2021 is set out below:

 

 i 
   Warrants   SAFE   Convertible loan   Financial Liability   Total 
Balance as of December 31, 2020    i 219     i 1,273    
-
    
-
     i 1,492 
Gains (losses) recognized in profit or loss   ( i 19)    i 2,330     i 612     i 450     i 3,373 
Additions   
-
     i 4,161     i 3,047     i 310     i 7,518 
Interest   
-
          i 60    
-
     i 60 
Conversion   
-
    ( i 6,680)   ( i 3,361)   ( i 656)   ( i 10,697)
Adjustments arising from translating financial operation   ( i 4)   ( i 45)   ( i 4)    i 29    ( i 24)
Balance as of December,31 2021    i 196     i 1,039     i 354     i 133     i 1,722 
 / 

 

F-37

 

 i International Financial Reporting Standards  i   i   i   i   i   i   i   i   i 0.95  i 3.67  i 3.2  i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i  Less than one thousand dollars  i   i   i 0.95  i 3.67  i 3.2  i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i true  i FY  i 0001837493 0001837493 2022-01-01 2022-12-31 0001837493 dei:BusinessContactMember 2022-01-01 2022-12-31 0001837493 2022-12-31 0001837493 2021-12-31 0001837493 2021-01-01 2021-12-31 0001837493 2020-01-01 2020-12-31 0001837493 ifrs-full:OrdinarySharesMember 2021-12-31 0001837493 ifrs-full:IssuedCapitalMember 2021-12-31 0001837493 ifrs-full:RetainedEarningsMember 2021-12-31 0001837493 ifrs-full:OrdinarySharesMember 2022-01-01 2022-12-31 0001837493 ifrs-full:IssuedCapitalMember 2022-01-01 2022-12-31 0001837493 ifrs-full:RetainedEarningsMember 2022-01-01 2022-12-31 0001837493 ifrs-full:OrdinarySharesMember 2022-12-31 0001837493 ifrs-full:IssuedCapitalMember 2022-12-31 0001837493 ifrs-full:RetainedEarningsMember 2022-12-31 0001837493 ifrs-full:OrdinarySharesMember 2020-12-31 0001837493 ifrs-full:AdditionalPaidinCapitalMember 2020-12-31 0001837493 ifrs-full:IssuedCapitalMember 2020-12-31 0001837493 ifrs-full:RetainedEarningsMember 2020-12-31 0001837493 2020-12-31 0001837493 ifrs-full:OrdinarySharesMember 2021-01-01 2021-12-31 0001837493 ifrs-full:AdditionalPaidinCapitalMember 2021-01-01 2021-12-31 0001837493 ifrs-full:IssuedCapitalMember 2021-01-01 2021-12-31 0001837493 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001837493 ifrs-full:AdditionalPaidinCapitalMember 2021-12-31 0001837493 ifrs-full:OrdinarySharesMember 2019-12-31 0001837493 ifrs-full:AdditionalPaidinCapitalMember 2019-12-31 0001837493 ifrs-full:IssuedCapitalMember 2019-12-31 0001837493 ifrs-full:RetainedEarningsMember 2019-12-31 0001837493 2019-12-31 0001837493 ifrs-full:OrdinarySharesMember 2020-01-01 2020-12-31 0001837493 ifrs-full:AdditionalPaidinCapitalMember 2020-01-01 2020-12-31 0001837493 ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001837493 ifrs-full:RetainedEarningsMember 2020-01-01 2020-12-31 0001837493 2021-07-16 0001837493 2021-07-01 2021-07-16 0001837493 2021-10-31 0001837493 2021-10-01 2021-10-31 0001837493 iinn:ComputersMember 2022-01-01 2022-12-31 0001837493 iinn:DevelopmentEquipmentMember 2022-01-01 2022-12-31 0001837493 iinn:FurnitureAndOfficeEquipmentMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001837493 iinn:FurnitureAndOfficeEquipmentMember ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001837493 iinn:LeaseholdImprovementMember 2022-01-01 2022-12-31 0001837493 2022-05-10 0001837493 2022-08-11 0001837493 2022-08-24 0001837493 ifrs-full:ComputerEquipmentMember 2021-12-31 0001837493 ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001837493 iinn:DevelopmentEquipmentMember 2021-12-31 0001837493 ifrs-full:OfficeEquipmentMember 2021-12-31 0001837493 ifrs-full:ComputerEquipmentMember 2022-01-01 2022-12-31 0001837493 ifrs-full:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001837493 ifrs-full:OfficeEquipmentMember 2022-01-01 2022-12-31 0001837493 ifrs-full:ComputerEquipmentMember 2022-12-31 0001837493 ifrs-full:LeaseholdImprovementsMember 2022-12-31 0001837493 iinn:DevelopmentEquipmentMember 2022-12-31 0001837493 ifrs-full:OfficeEquipmentMember 2022-12-31 0001837493 ifrs-full:ComputerEquipmentMember 2020-12-31 0001837493 ifrs-full:LeaseholdImprovementsMember 2020-12-31 0001837493 iinn:DevelopmentEquipmentMember 2020-12-31 0001837493 ifrs-full:OfficeEquipmentMember 2020-12-31 0001837493 ifrs-full:ComputerEquipmentMember 2021-01-01 2021-12-31 0001837493 ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001837493 iinn:DevelopmentEquipmentMember 2021-01-01 2021-12-31 0001837493 ifrs-full:OfficeEquipmentMember 2021-01-01 2021-12-31 0001837493 iinn:WarrantsToInvestorsMember 2021-07-01 2021-07-16 0001837493 iinn:WarrantsToBrokersMember 2021-07-01 2021-07-16 0001837493 iinn:InitialPublicOfferingMember 2022-01-01 2022-12-31 0001837493 2021-10-01 2022-10-31 0001837493 iinn:NontradableWarrantsMember 2022-01-01 2022-12-31 0001837493 iinn:NontradableWarrantsMember 2021-01-01 2021-12-31 0001837493 iinn:NontradableWarrantsSAFEAndCLAMember 2022-01-01 2022-12-31 0001837493 iinn:NontradableWarrantsSAFEAndCLAMember 2021-01-01 2021-12-31 0001837493 iinn:TradableWarrantsMember 2022-01-01 2022-12-31 0001837493 iinn:TradableWarrantsMember 2021-01-01 2021-12-31 0001837493 iinn:FinancialLiabilityMember 2022-01-01 2022-12-31 0001837493 iinn:FinancialLiabilityMember 2021-01-01 2021-12-31 0001837493 iinn:InvestorsMember 2022-01-01 2022-12-31 0001837493 ifrs-full:TopOfRangeMember 2021-03-18 2021-03-18 0001837493 ifrs-full:BottomOfRangeMember 2021-03-18 2021-03-18 0001837493 2021-03-18 0001837493 ifrs-full:TopOfRangeMember 2021-06-01 2021-06-01 0001837493 ifrs-full:BottomOfRangeMember 2021-06-01 2021-06-01 0001837493 2021-06-01 0001837493 ifrs-full:OrdinarySharesMember 2021-06-01 2021-06-01 0001837493 iinn:OverallotmentOptionMember 2021-07-16 0001837493 iinn:BrokersMember 2022-01-01 2022-12-31 0001837493 ifrs-full:OrdinarySharesMember 2022-01-01 2022-12-31 0001837493 2021-12-17 0001837493 iinn:FinancialIncomeMember 2022-12-31 0001837493 iinn:FinancialIncomeMember 2021-12-31 0001837493 iinn:FinancialIncomeMember 2020-12-31 0001837493 iinn:FinancialIncomeMember 2022-01-01 2022-12-31 0001837493 iinn:FinancialIncomeMember 2021-01-01 2021-12-31 0001837493 iinn:FinancialIncomeMember 2020-01-01 2020-12-31 0001837493 iinn:FinancialExpensesMember 2022-12-31 0001837493 iinn:FinancialExpensesMember 2021-12-31 0001837493 iinn:FinancialExpensesMember 2020-12-31 0001837493 iinn:FinancialExpensesMember 2022-01-01 2022-12-31 0001837493 iinn:FinancialExpensesMember 2021-01-01 2021-12-31 0001837493 iinn:FinancialExpensesMember 2020-01-01 2020-12-31 0001837493 ifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001837493 ifrs-full:VehiclesMember 2022-12-31 0001837493 ifrs-full:LeaseReceivablesMember 2022-01-01 2022-12-31 0001837493 ifrs-full:LeaseReceivablesMember 2022-12-31 0001837493 srt:OfficeBuildingMember 2021-12-31 0001837493 ifrs-full:VehiclesMember 2021-12-31 0001837493 srt:OfficeBuildingMember 2022-01-01 2022-12-31 0001837493 ifrs-full:VehiclesMember 2022-01-01 2022-12-31 0001837493 srt:OfficeBuildingMember 2022-12-31 0001837493 ifrs-full:VehiclesMember 2022-12-31 0001837493 2019-01-01 2019-12-31 0001837493 2020-04-01 2020-04-20 0001837493 2020-12-01 2020-12-17 0001837493 2020-12-01 2020-12-20 0001837493 2021-02-01 2021-02-21 0001837493 2021-03-01 2021-03-16 0001837493 2021-03-16 0001837493 srt:DirectorMember 2021-08-01 2021-08-12 0001837493 2021-08-01 2021-08-12 0001837493 srt:DirectorMember 2021-11-02 2021-11-02 0001837493 ifrs-full:OrdinarySharesMember 2021-11-02 2021-11-02 0001837493 2021-11-02 2021-11-02 0001837493 2022-03-01 2022-03-24 0001837493 2022-04-01 2022-04-06 0001837493 2022-05-01 2022-05-19 0001837493 2022-11-01 2022-11-22 0001837493 iinn:AdvisersMember 2022-01-01 2022-12-31 0001837493 iinn:DirectorsMember 2022-01-01 2022-12-31 0001837493 iinn:RSUMember 2022-01-01 2022-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2021-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2022-01-01 2022-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2021-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-01-01 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2020-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2021-01-01 2021-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2020-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2021-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2022-01-01 2022-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2021-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-01-01 2022-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2022-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2020-12-31 0001837493 iinn:ProvidersAndAdvisersMember 2021-01-01 2021-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2020-12-31 0001837493 iinn:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001837493 iinn:EmployeesMember 2022-01-01 2022-12-31 0001837493 iinn:EmployeesMember 2021-01-01 2021-12-31 0001837493 iinn:DirectorsMember 2022-01-01 2022-12-31 0001837493 iinn:DirectorsMember 2021-01-01 2021-12-31 0001837493 ifrs-full:CreditRiskMember 2022-12-31 0001837493 ifrs-full:CreditRiskMember 2021-12-31 0001837493 iinn:USDMemberMember 2022-01-01 2022-12-31 0001837493 iinn:USDMemberMember 2021-01-01 2021-12-31 0001837493 iinn:AUDMember 2022-01-01 2022-12-31 0001837493 iinn:AUDMember 2021-01-01 2021-12-31 0001837493 iinn:PoundMember 2022-01-01 2022-12-31 0001837493 iinn:PoundMember 2021-01-01 2021-12-31 0001837493 iinn:UpTo1YearMember 2022-12-31 0001837493 iinn:Between1And3YearsMember 2022-12-31 0001837493 iinn:MoreThan3YearsMember 2022-12-31 0001837493 iinn:UpTo1YearMember 2021-12-31 0001837493 iinn:Between1And3YearsMember 2021-12-31 0001837493 iinn:MoreThan3YearsMember 2021-12-31 0001837493 ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001837493 ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001837493 ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001837493 iinn:fairValueMeasurementAtLevel2Member ifrs-full:BottomOfRangeMember 2022-01-01 2022-12-31 0001837493 iinn:fairValueMeasurementAtLevel2Member ifrs-full:TopOfRangeMember 2022-01-01 2022-12-31 0001837493 iinn:fairValueMeasurementAtLevel2Member 2022-01-01 2022-12-31 0001837493 ifrs-full:Level1OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001837493 ifrs-full:Level2OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001837493 ifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-12-31 0001837493 ifrs-full:Level1OfFairValueHierarchyMember 2022-12-31 0001837493 ifrs-full:Level2OfFairValueHierarchyMember 2022-12-31 0001837493 ifrs-full:Level3OfFairValueHierarchyMember 2022-12-31 0001837493 ifrs-full:Level1OfFairValueHierarchyMember 2021-01-01 2021-12-31 0001837493 ifrs-full:Level2OfFairValueHierarchyMember 2021-01-01 2021-12-31 0001837493 ifrs-full:Level3OfFairValueHierarchyMember 2021-01-01 2021-12-31 0001837493 ifrs-full:Level1OfFairValueHierarchyMember 2021-12-31 0001837493 ifrs-full:Level2OfFairValueHierarchyMember 2021-12-31 0001837493 ifrs-full:Level3OfFairValueHierarchyMember 2021-12-31 0001837493 iinn:WarrantsMember 2021-12-31 0001837493 iinn:SAFEMember 2021-12-31 0001837493 iinn:ConvertibleLoanMember 2021-12-31 0001837493 iinn:FinancialDerivativeMember 2021-12-31 0001837493 iinn:WarrantsMember 2021-01-01 2021-12-31 0001837493 iinn:SAFEMember 2021-01-01 2021-12-31 0001837493 iinn:ConvertibleLoanMember 2021-01-01 2021-12-31 0001837493 iinn:FinancialDerivativeMember 2021-01-01 2021-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:ILS xbrli:shares

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F/A’ Filing    Date    Other Filings
Filed as of:4/20/23
Filed on:4/19/23
3/28/23
3/8/23
For Period end:12/31/2220-F
11/22/226-K
11/9/22
11/8/22
8/24/22
8/11/226-K
7/1/22
5/19/226-K
5/10/22
4/6/226-K
3/24/22
3/4/22
2/24/22
1/1/22
12/31/2120-F
12/17/21
11/2/21
8/12/21
7/16/216-K
6/1/21
3/18/21
3/16/21
2/21/21
1/1/21
12/31/20
12/20/20
12/17/20
4/20/20
1/1/20
2/27/18
4/5/12
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/24  Inspira Techs OXY B.H.N. Ltd.     S-8         3/15/24    4:92K                                    EdgarAgents LLC/FA
10/10/23  Inspira Techs OXY B.H.N. Ltd.     POS AM                 2:279K                                   MDM Corp Elec Fi… Inc/FA


6 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/23  Inspira Techs OXY B.H.N. Ltd.     20-F       12/31/22  102:9.4M                                   EdgarAgents LLC/FA
12/20/21  Inspira Techs OXY B.H.N. Ltd.     6-K        12/20/21    3:411K                                   EdgarAgents LLC/FA
10/27/21  Inspira Techs OXY B.H.N. Ltd.     POS AM                 3:1.2M                                   EdgarAgents LLC/FA
 6/28/21  Inspira Techs OXY B.H.N. Ltd.     F-1/A                  7:2.3M                                   EdgarAgents LLC/FA
 6/08/21  Inspira Techs OXY B.H.N. Ltd.     F-1/A                  8:2.6M                                   EdgarAgents LLC/FA
 3/12/21  Inspira Techs OXY B.H.N. Ltd.     F-1/A                 11:17M                                    EdgarAgents LLC/FA
Top
Filing Submission 0001213900-23-031088   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 8, 10:58:41.2am ET